PROCEPT BioRobotics Strategy and Business Model

Executive Overview

PROCEPT BioRobotics is a surgical robotics company focused on urology, specifically the treatment of benign prostatic hyperplasia (BPH), a common enlargement of the prostate that can cause lower urinary tract symptoms. Founded in 2007 and headquartered in San Jose, California, the company commercializes Aquablation therapy through its AQUABEAM robotic platform. The system combines real-time imaging with a robotically controlled waterjet to remove prostate tissue in a heat-free procedure. Strategically, PROCEPT is building an installed-base medtech model: hospitals and ambulatory surgery centers acquire the capital system, then generate recurring revenue through procedure-linked single-use handpieces and service. That makes procedure utilization after installation almost as important as the initial system sale. The company operates in the broader surgical robotics and urology-device market, but its practical competition comes less from a like-for-like robotic rival and more from entrenched BPH treatments such as transurethral resection of the prostate, laser procedures, UroLift, and Rezūm. The U.S. is its core market, with a growing international footprint in selected countries. PROCEPT reported FY2023 revenue of $136.4 million.

PROCEPT BioRobotics at a Glance

Logo
Common name	PROCEPT BioRobotics
Full legal name	PROCEPT BioRobotics Corporation
Headquarters	San Jose, California, United States
Ownership	Public company
Ticker	PRCT
Exchange	NASDAQ
Market Cap	$1.17B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2007; U.S. FDA clearance for the AQUABEAM system in 2017; commercialization scaled in the late 2010s; Nasdaq IPO in 2021
Industry or industries	Medical devices, surgical robotics, urology
Key products or services	AQUABEAM robotic systems, Aquablation therapy handpieces and consumables, service and support
Geographic footprint	Primarily United States, with growing presence in selected international markets through direct and distributor channels
Business segments as officially reported	One operating and reportable segment
Company website	https://www.procept-biorobotics.com/

1. What Is the Strategy of PROCEPT BioRobotics?

PROCEPT BioRobotics is best understood as a focused, single-platform medtech company trying to redefine one important urology procedure category rather than as a broad medical-device conglomerate. Its public filings and investor materials point to a clear strategic logic: build a differentiated clinical standard in BPH surgery, place more robotic systems, and turn those placements into durable recurring revenue through procedure growth.

1. 1a. What is the winning aspiration of PROCEPT BioRobotics?

   PROCEPT’s implicit winning aspiration is to make Aquablation therapy a standard surgical option for men with BPH and to become the category leader in robotic intervention for that indication. In public communications through FY2023 and early 2024, management consistently framed the opportunity around changing the treatment paradigm in a large, underpenetrated market rather than simply selling capital equipment. The company has not centered its strategy on one evergreen long-term public revenue target; instead, winning is described more practically through broader system adoption, rising procedure volumes, expanding clinical acceptance, and stronger recurring handpiece revenue.

2. 1b. Where does PROCEPT BioRobotics play?

   PROCEPT plays in the surgical treatment of BPH, with a particular focus on hospitals, health systems, and increasingly outpatient sites that perform urologic procedures. Its primary clinical users are urologists, while its economic buyers include hospital administrators, purchasing committees, and ambulatory surgery center operators. Geographically, the company plays first and foremost in the U.S., then selectively in international markets where reimbursement, capital budgets, and surgeon adoption can support a premium robotic platform. Product-wise, it is concentrated around one core platform and its related disposables, not a broad multi-specialty portfolio.

3. 1c. How does PROCEPT BioRobotics plan to win?

   PROCEPT plans to win through differentiation, not cost leadership. The company’s value proposition is that Aquablation combines robotic execution with real-time imaging to deliver reproducible tissue resection without thermal energy. In practice, that means PROCEPT is asking hospitals and surgeons to choose its system because of clinical outcomes, procedural consistency, and workflow value, not because it is the lowest-cost device option. Management also appears to believe that a strong evidence base, surgeon training, and simpler reproducibility can help it compete against both traditional procedures and minimally invasive alternatives.

4. 1d. What capabilities must PROCEPT BioRobotics have in place?

   To execute this strategy, PROCEPT needs a tight set of capabilities: product engineering in robotics and imaging; clinical-trial and outcomes-generation capability; regulatory and quality-system discipline; a specialized capital-equipment sales force; field clinical teams that can train and support surgeons; and dependable manufacturing for both consoles and sterile disposable handpieces. It also needs reimbursement and health-economics capability, because procedure adoption depends not just on surgeon preference but on whether hospitals can justify the economics.

5. 1e. What management systems does PROCEPT BioRobotics require?

   PROCEPT requires management systems typical of a scaling medtech company: design controls, post-market surveillance, complaint handling, supplier quality management, and regulatory compliance. Commercially, it needs rigorous installed-base tracking, utilization metrics, procedure pull-through analytics, and service-response systems. Strategically, it needs capital allocation disciplines that balance near-term growth spending with longer-term margin improvement. Because the business model depends on both placements and recurring use, management has to measure success at the account level over time, not just at the moment of sale.

2. What Are the Current Strategic Initiatives of PROCEPT BioRobotics?

Based on PROCEPT’s FY2023 Form 10-K, investor communications, and early 2024 commentary, the company’s current strategic initiatives appear to be concentrated in a small number of highly practical areas.

• Expand the U.S. installed base. The first priority is continued system placement in U.S. hospitals and urology centers. This is the core engine of future recurring revenue because every additional installed system can generate handpiece, service, and training demand over time.
• Increase utilization at existing accounts. A placed system is only economically valuable if surgeons use it consistently. PROCEPT has therefore emphasized surgeon training, clinical support, and account development so that sites move from initial adoption to regular procedure volume.
• Support broader site-of-care adoption. Management has publicly highlighted newer platform capabilities, including the HYDROS Robotic System, as part of a roadmap to improve workflow and reduce adoption friction. Strategically, this matters because smaller footprint, easier setup, and more efficient procedures can help the company reach more outpatient-oriented environments.
• Deepen clinical evidence and guideline support. PROCEPT continues to invest in clinical data and long-term outcomes. For a company competing against well-known procedures, evidence is not a marketing extra; it is a strategic necessity for surgeon conversion, hospital value-analysis approval, and reimbursement confidence.
• Selective international expansion. The company is growing outside the U.S. in selected markets rather than trying to enter every country at once. That measured approach fits a capital-equipment business that needs local training, reimbursement understanding, and post-sale service capability.
• Scale operations and improve margins. As revenue grows, management is also working on the less visible side of the model: manufacturing scale, supply reliability, and mix improvement. That matters because recurring disposables and better production economics can improve gross margin over time even if the company remains in investment mode at the operating level.

3. What Is the Business Model of PROCEPT BioRobotics?

What customers actually buy

Customers do not just buy a robot. They buy a procedural platform for treating BPH. That platform typically includes the capital system, the disposable handpiece used in each procedure, service and maintenance, and training that enables urologists and operating-room teams to use the technology safely and consistently.

What portion of the model appears recurring or repeat-driven versus one-time

PROCEPT’s model has a classic medtech split between one-time and recurring revenue. The system placement is more episodic and tied to hospital capital budgets. The handpieces and related procedure consumables are repeat-driven and become more valuable as utilization rises. Service contracts add another recurring layer. Strategically, that means the quality of revenue should improve as the installed base matures.

How pricing power works

Pricing power is stronger in the clinical value proposition than in pure list-price escalation. Capital systems face negotiation, budget scrutiny, and internal hospital approval processes. Once a site has adopted the platform and built procedural workflow around it, PROCEPT has somewhat better pricing resilience in disposables and service, although hospitals still monitor per-procedure economics closely.

Why the business mix matters

The mix between systems and handpieces matters because systems build the installed base, while handpieces drive repeat economics. A company with rising system sales but weak utilization can look busy without becoming structurally stronger. By contrast, strong pull-through at existing sites can improve margin quality and make future growth more durable.

What drives gross margin, operating margin, and cash generation

Gross margin is driven by manufacturing scale, component costs, service efficiency, and mix shift toward recurring handpieces and service. Operating margin is still heavily affected by commercial investment, especially sales, marketing, clinical support, and R&D. Cash generation depends not only on revenue growth but also on inventory management, collections from capital equipment sales, and the pace at which recurring procedure revenue begins to outgrow the fixed cost base.

Revenue model

This is not a subscription business. It is an installed-base medical-device model with capital equipment, procedure-linked disposable revenue, and service revenue. In that respect, PROCEPT looks closer to other surgical technology companies that place platforms and monetize utilization over time.

4. What Products and/or Services Does PROCEPT BioRobotics Sell?

PROCEPT remains tightly focused on one clinical platform rather than a broad product catalog. That concentration is strategically important: it simplifies the story, but it also means execution on one franchise matters disproportionately.

• AQUABEAM Robotic System. This is the company’s core capital platform used to perform Aquablation therapy for BPH. It is the anchor of the business because it creates the installed base from which recurring revenue flows.
• Aquablation therapy handpieces and procedure consumables. These single-use components are tied to each procedure and are therefore the most important recurring revenue stream. As the installed base grows and surgeons perform more cases, these products become increasingly central to the economics of the business.
• Service, maintenance, and support. Hospitals buying surgical technology need uptime, preventive maintenance, and technical support. Service revenue is smaller than product revenue, but it supports retention and helps protect utilization.
• Next-generation platform enhancements. PROCEPT has publicly introduced the HYDROS Robotic System as part of its platform evolution. Strategically, newer system generations matter not because they create a separate product family, but because they can reduce workflow friction, improve usability, and widen the addressable site-of-care base.

There is little true legacy-versus-growth portfolio tension here. PROCEPT is still primarily a one-platform company, so the main distinction is between its current installed base and the newer capabilities it adds to make that platform easier to adopt and scale.

5. What Are the Key Competitors or Peers of PROCEPT BioRobotics?

PROCEPT has limited like-for-like robotic competition in BPH. In practical terms, it competes against alternative procedures and the device companies that enable them. It is also useful to distinguish between direct procedure competition and broader business-model peers.

The important competitive insight is that PROCEPT is usually trying to displace existing surgeon habits and hospital workflows, not just outperform another robotic BPH company on a spec sheet.

6. What Is the Marketing Strategy of PROCEPT BioRobotics?

PROCEPT’s marketing strategy appears to be primarily clinical and account-based rather than mass-market. The company has to persuade two audiences at the same time: urologists who care about outcomes, reproducibility, and workflow; and hospital or ambulatory surgery center decision-makers who care about capital spending, utilization, and procedure economics.

That makes clinical evidence central to marketing. Peer-reviewed data, long-term follow-up, conference presence, key opinion leader advocacy, and surgeon training matter more here than broad consumer brand advertising. Professional society meetings and physician education are therefore likely more important channels than traditional brand media.

There is also a practical patient-awareness element. Men with BPH often research treatment options before seeing a urologist, so disease education and procedure awareness can support physician demand generation. Even so, PROCEPT’s marketing appears to function mainly as a supporting capability to the sales model rather than as a standalone consumer brand machine.

7. What Are the Key Customer Segments of PROCEPT BioRobotics?

PROCEPT’s customer base is concentrated by specialty but multi-layered by buying role.

• Hospitals and health systems. These are the primary economic buyers of capital systems in the U.S. They matter because they control capital budgets, operating-room capacity, and service contracts.
• Ambulatory surgery centers and outpatient facilities. This is an increasingly important segment as PROCEPT works to broaden site-of-care adoption. These customers are especially sensitive to workflow efficiency, footprint, and unit economics.
• Urologists and urology groups. They are the clinical users and often the internal champions for adoption. Their willingness to train, change procedure patterns, and build case volume is critical.
• International distributors and hospital buyers. Outside the U.S., distributors and local commercial partners can be important channel customers where PROCEPT does not sell directly.
• Patients as indirect demand drivers. Patients do not usually buy the system, but their treatment preferences and conversations with urologists can influence procedure mix.

The company is diversified across provider types but not across end markets. It is still highly concentrated in one disease area, one specialty, and one procedural category.

8. What Is the Sales Model of PROCEPT BioRobotics?

PROCEPT uses a specialized medtech sales model built around direct capital sales, clinical support, and recurring consumable pull-through. In the U.S., the company relies heavily on direct commercial teams that work with hospital administrators, value-analysis committees, and physicians. In selected international markets, it uses a mix of direct presence and distributor relationships.

The sales cycle for a capital system is typically longer than the sale of a disposable device. It can involve clinical champion development, business-case justification, committee approval, installation planning, and post-sale training. That makes field clinical specialists a strategically important part of the go-to-market model. They help convert a purchase into active utilization.

This channel structure has several effects. It improves customer intimacy and account-level visibility, which is valuable in a utilization-driven business. It also increases selling expense and execution complexity. For consultants, this kind of model creates clear opportunities in territory design, pipeline management, post-install adoption, distributor governance, and sales-force productivity.

9. In What Geographies Does PROCEPT BioRobotics Operate?

PROCEPT operates primarily in the United States, which has been its largest market by a wide margin in recent public disclosures. That concentration makes sense: the U.S. offers a large base of BPH procedures, sophisticated hospital buyers, and a pathway to scale for premium medical technology.

Internationally, the company has been expanding in selected markets rather than attempting global saturation all at once. Its public materials indicate a growing presence outside the U.S. through a combination of direct operations and distributor channels in selected countries, particularly in developed healthcare markets where reimbursement, urologist training, and service coverage are more feasible.

Physically, PROCEPT does not need a vast branch network in the way a distributor would, but it does need commercial, training, installation, and service coverage close enough to support live surgical accounts. Its geographic strategy therefore appears focused on depth in a manageable set of markets rather than broad but thin coverage.

10. Who Are the Owners of PROCEPT BioRobotics?

PROCEPT BioRobotics is a public company with dispersed ownership and no controlling shareholder disclosed in its 2024 proxy materials. Ownership is primarily institutional, which is typical for a growth-stage listed medtech company.

• FMR LLC was among the large institutional holders disclosed in SEC filings around early 2024.
• The Vanguard Group was also among the large institutional holders disclosed around early 2024.
• Management and directors, including founder-CEO Reza Zadno, held minority equity stakes, aligning leadership with shareholder value creation but not constituting control.

11. How Is PROCEPT BioRobotics Organized?

Officially, PROCEPT reports as one operating and reportable segment. That is important because it means investors should not expect detailed segment-level disclosure by geography or product line. Economically, however, the business can still be understood through a few practical operating groups.

At a working level, PROCEPT appears organized around: commercial teams; field clinical and medical education teams; research and development; operations and supply chain; quality and regulatory affairs; and corporate functions such as finance and legal. Commercially, the business is effectively split between the U.S. core market and a smaller international operation.

This is a relatively streamlined structure for a public medtech company. The advantage is focus. The tradeoff is concentration: one platform, one main specialty, and one broad segment mean management execution matters more than portfolio balancing.

12. How Does PROCEPT BioRobotics Operate?

Day to day, PROCEPT operates as an integrated surgical-platform company with four linked operating loops.

1. Develop and validate the platform. The company designs, tests, and updates its robotic system, handpieces, and related software while maintaining quality and regulatory compliance.
2. Win and install accounts. Commercial teams sell the system, coordinate installation, and help the customer prepare clinically and operationally for use.
3. Train physicians and support procedures. Clinical support is critical during early cases. Adoption can stall if physicians are not trained well enough or if operating-room workflow is cumbersome.
4. Replenish disposables and maintain uptime. Once a site is active, PROCEPT has to supply handpieces reliably, service the installed base, and keep procedure experience consistent so utilization rises rather than fades.

The major operational bottlenecks are typical of a scaling medtech platform: capital approval cycles, surgeon training throughput, supplier reliability, service response, and maintaining quality while volumes increase. Because hospitals schedule procedures in advance, a supply or service disruption can damage both revenue and trust.

13. What Are the Growth Opportunities for PROCEPT BioRobotics?

PROCEPT’s growth opportunities are clear, but so are the constraints. The most plausible paths are listed below.

A reasonable external synthesis is that PROCEPT has room to grow for years if it can keep converting clinical interest into routine procedural volume. The biggest risk is not lack of market size; it is the difficulty of changing hospital workflows and surgeon habits at scale.

14. What Is the History of PROCEPT BioRobotics?

PROCEPT BioRobotics was founded in 2007 to commercialize Aquablation technology for BPH treatment. The company has been led through much of its development by founder-CEO Reza Zadno, which gives it a relatively founder-led profile for a public medtech company.

• 2007: Company founded to develop a robotic, image-guided approach to prostate tissue removal.
• 2010s: PROCEPT spent much of its early life in product development, clinical validation, and regulatory preparation rather than broad commercial scale.
• 2017: The AQUABEAM system received U.S. Food and Drug Administration clearance, a major milestone that enabled U.S. commercialization.
• Late 2010s to early 2020s: The company expanded clinical evidence and commercial adoption while building its direct sales and support infrastructure.
• 2021: PROCEPT completed its initial public offering and became listed on Nasdaq under the ticker PRCT.
• 2023 and beyond: The company entered a more explicit scale-up phase, emphasizing installed-base growth, utilization, international expansion, and platform evolution.

Notably, PROCEPT’s story has been driven more by organic development and commercialization than by major acquisitions or conglomerate-style portfolio reshaping.

15. What Are the Key Suppliers to PROCEPT BioRobotics?

Suppliers matter meaningfully to PROCEPT because its products combine specialized capital equipment with sterile single-use procedure components. In its public filings, the company has indicated dependence on third-party suppliers, including sole-source or limited-source arrangements for certain items, which is common in medtech but strategically important.

• Precision component suppliers for robotic, fluid-control, and mechanical assemblies
• Electronics and subsystem suppliers for control systems and hardware integration
• Disposable manufacturing and sterilization partners for procedure-linked handpieces and related consumables
• Imaging-related component suppliers supporting the system’s visualization capabilities
• Logistics and service-part vendors that help maintain field uptime

PROCEPT does not publicly emphasize a single branded supplier in the way an automaker might. The strategic issue is less supplier name recognition and more supply assurance, quality consistency, and cost control.

16. What Are the Key Brands Owned by PROCEPT BioRobotics?

PROCEPT is not a house-of-brands company. Its branding is concentrated in a small number of closely linked procedure and platform names.

• Aquablation therapy. This is the core procedure brand. It is strategically important because it describes the clinical experience and gives physicians and patients a memorable way to distinguish the treatment from competing BPH procedures.
• AQUABEAM Robotic System. This is the main platform brand tied to the capital equipment. It carries most of the company’s installed-base identity.
• HYDROS Robotic System. This newer platform name represents PROCEPT’s effort to evolve the product and support broader adoption through workflow and usability improvements.

Branding matters here, but mainly as a reinforcement of clinical differentiation and procedure familiarity rather than as a consumer packaged-goods style demand engine.

17. How Does the Supply Chain of PROCEPT BioRobotics Function?

PROCEPT’s supply chain has to support two different product rhythms at once: lower-volume capital systems and higher-frequency disposable handpieces. That makes planning more complex than it would be for a pure equipment maker or a pure disposable supplier.

1. Component sourcing: the company procures specialized parts and subassemblies from qualified suppliers under medical-device quality requirements.
2. System production and testing: robotic systems must be assembled, tested, and released under strict quality procedures before customer installation.
3. Disposable production and sterilization: single-use handpieces require reliable manufacturing, sterility assurance, and inventory planning tied to case volume.
4. Installation and field service logistics: the company must deliver systems, support installations, and keep spare parts available for uptime.
5. Replenishment: ongoing procedure volume creates repeat orders that require dependable forecasting and fulfillment.

Supply-chain reliability matters strategically because missed shipments can disrupt scheduled surgeries, while excess inventory can consume cash in a still-scaling business.

18. What Is the Technology Strategy of PROCEPT BioRobotics?

Technology is central to PROCEPT’s competitiveness because the product itself is a technology proposition, not merely a branded commodity device. The company’s strategy is to integrate imaging, robotics, fluidics, and software into a procedure that it argues can deliver consistent tissue removal with less dependence on manual resection skill alone.

There are three visible layers to that strategy. First, the company has to maintain clinical differentiation at the procedure level. Second, it has to improve usability, setup, and workflow so the technology becomes easier to adopt across more sites of care. Third, it has to make the installed base more valuable over time through product upgrades, serviceability, and continued evidence-backed refinement.

Technology also matters internally. Quality systems, engineering change control, and post-market monitoring are essential because small technical issues can have outsized consequences in a regulated surgical environment.

19. What Is the R&D Strategy of PROCEPT BioRobotics?

PROCEPT’s R&D strategy appears to combine product engineering with clinical evidence generation. For this company, those two activities are closely linked. A better robot is not enough if surgeons and hospitals do not trust the data behind it.

• Platform refinement: improving system workflow, usability, reliability, and procedure efficiency
• Disposable innovation: optimizing handpieces and procedure components that affect both performance and economics
• Clinical studies and long-term outcomes: extending the evidence base developed through trials such as WATER and WATER II to support adoption and reimbursement
• Site-of-care enablement: adapting the platform so it can work in a broader range of procedural environments
• Manufacturability: making design choices that support scale, quality, and gross margin improvement

This is a notable feature of PROCEPT’s strategy: clinical research is not separate from commercialization. It is one of the mechanisms by which commercialization becomes possible.

20. What Is the Finance Strategy of PROCEPT BioRobotics?

PROCEPT’s finance strategy is typical of a high-growth medtech company that is still building scale. The near-term objective is not to maximize reported earnings immediately. It is to invest capital in system placements, sales coverage, clinical support, product development, and manufacturing capability so the installed-base model can mature.

In practical terms, that means capital allocation appears focused on four priorities: commercial expansion, R&D, operational scale, and liquidity management. The company’s economics should improve as recurring handpieces become a larger share of revenue and as manufacturing and service costs are leveraged across a larger base. Until then, operating expense remains intentionally elevated relative to current revenue.

PROCEPT has not positioned itself as a dividend or buyback story. Public investors are being asked to underwrite growth and category creation first, with margin expansion expected to follow if utilization and scale continue to build.

21. How Companies Like PROCEPT BioRobotics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including many alumni of McKinsey, Bain, BCG, and other top firms. Companies like PROCEPT BioRobotics use Umbrex when they need that caliber of strategic and operational talent but do not need a full traditional consulting team with the associated overhead. For a focused medtech company scaling a differentiated platform, that model can be especially useful because the work often requires sharp expertise in one function, one market, or one transformation topic.

• U.S. market white-space analysis: map hospital systems, urology groups, and ambulatory surgery centers most likely to adopt Aquablation next.
• Installed-base utilization improvement: identify why some accounts ramp faster than others and design playbooks to increase procedure pull-through.
• ASC and outpatient site-of-care strategy: assess workflow, economics, and account-prioritization implications of expanding beyond traditional hospital settings.
• Capital equipment pricing and value proposition redesign: sharpen the economic case for administrators, value-analysis committees, and integrated delivery networks.
• International expansion strategy: prioritize countries, choose between direct and distributor models, and sequence entry based on reimbursement and service feasibility.
• Sales-force effectiveness project: redesign territories, account segmentation, pipeline management, and clinical-support deployment for a capital-plus-consumables model.
• Supply-chain resilience and cost-down program: reduce component risk, improve sourcing strategies, and lower unit costs on systems and disposables.
• R&D portfolio and stage-gate review: help management prioritize platform enhancements, workflow upgrades, and future product investments.
• Commercial launch PMO for next-generation systems: support coordinated rollout planning across manufacturing, training, sales, and service.
• Long-range plan and operating model design: build a fact-based roadmap for gross-margin improvement, international scale, and eventual operating leverage.